<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326636</url>
  </required_header>
  <id_info>
    <org_study_id>UCaliforniaIrvine [2013-9455]</org_study_id>
    <secondary_id>2013-9455</secondary_id>
    <nct_id>NCT02326636</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>FMT</acronym>
  <official_title>Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to investigate the efficacy of transplanting screened donor&#xD;
      fecal material in treating patients with recurrent Clostridium difficile infection.&#xD;
      Participants with refractory Clostridium difficile infection will be given healthy donor&#xD;
      stool administered by colonoscopy or enema and their response will be evaluated by symptom&#xD;
      questionnaire and stool testing for Clostridium difficile at 4 weeks after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 26, 2018</completion_date>
  <primary_completion_date type="Actual">October 26, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence rate of Clostridium difficile 4 weeks after FMT.</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms from before fecal microbiota transplant (FMT) to 4 weeks after FMT.</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the FMT procedure. ( satisfaction questionnaire )</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Subjects will complete a satisfaction questionnaire following the FMT procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before and 4 weeks after FMT.</measure>
    <time_frame>Four weeks</time_frame>
    <description>Subjects will complete a quality of life questionnaire before and 4 weeks after FMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alternate treatments needed for Clostridium difficile before and after FMT.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Subjects medication and treatment history for Clostridium difficile before and after FMT will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of adverse events that may be related to FMT.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbial Transplantation</intervention_name>
    <description>Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A donor stool sample will be kept for future testing in case of contamination.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are referred for recurrent Clostridium difficile infections. Donors will be&#xD;
        identified by the Recipient.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Recipient:&#xD;
&#xD;
          -  Between the age of 18 and 100&#xD;
&#xD;
          -  Have positive Clostridium difficile polymerase chain reaction (PCR) or toxin&#xD;
&#xD;
          -  Have symptoms of &gt; 3 watery loose stools a day for at least 2 consecutive days&#xD;
&#xD;
          -  Have failed at least one prior standard course of antibiotic therapy.&#xD;
&#xD;
        Examples of standard therapy are:&#xD;
&#xD;
          -  Metronidazole 500 mg three times a day for 10 to 14 days&#xD;
&#xD;
          -  Vancomycin 125 mg four times a day for 10 to 14 days&#xD;
&#xD;
          -  Not be pregnant and have negative urine and/or serum human chorionic gonadotropin&#xD;
             (hCG) test&#xD;
&#xD;
          -  Not be taking oral or intravenous steroids in the past three months.&#xD;
&#xD;
          -  Not on biologic agents, anti-tumor necrosis factor (anti-TNF) agents, cyclosporine,&#xD;
             mercaptopurine, azathioprine, methotrexate or chemotherapy in the preceding 3 months&#xD;
&#xD;
          -  Not have profound immunosuppression: Chemotherapy the preceding 3 months, HIV/AIDS,&#xD;
             decompensated cirrhosis&#xD;
&#xD;
          -  Not be in the Intensive Care Unit&#xD;
&#xD;
          -  Not be a transplant recipient&#xD;
&#xD;
        Exclusion Criteria for Recipient:&#xD;
&#xD;
          -  Not between the age of 18 and 100&#xD;
&#xD;
          -  Does not have positive Clostridium difficile PCR or toxin&#xD;
&#xD;
          -  Does not have symptoms of &gt; 3 watery loose stools a day for at least 2 consecutive&#xD;
             days&#xD;
&#xD;
          -  Has not failed at least one prior standard course of antibiotic therapy. Examples of&#xD;
             standard therapy are:&#xD;
&#xD;
          -  Metronidazole 500 mg three times a day for 10 to 14 days&#xD;
&#xD;
          -  Vancomycin 125 mg four times a day for 10 to 14 days&#xD;
&#xD;
          -  Is pregnant&#xD;
&#xD;
          -  Has taken oral or IV steroids in the past three months.&#xD;
&#xD;
          -  Has taken biologic agents, anti-TNF agents, cyclosporine, mercaptopurine,&#xD;
             azathioprine, methotrexate or chemotherapy in the preceding 3 months&#xD;
&#xD;
          -  Has profound immunosuppression: Chemotherapy the preceding 3 months, HIV/AIDS,&#xD;
             decompensated cirrhosis&#xD;
&#xD;
          -  In the Intensive Care Unit&#xD;
&#xD;
          -  Is a transplant recipient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimisha Parekh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

